This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
And then into the outpatient and inpatient settings—are we treating the right patients in the inpatient setting that need to be treated? Author(s): Alexandra Gerlach, Associate Editor , Scott A. Then we filter that all the way down into the clinic, about how do we, you know, move patients in and out of the system?
2 “I think what’s going to be really interesting with finerenone is [whether] it is an inpatient or an outpatient drug,” said Katherine Di Palo, PharmD, MBA, MS, senior director of transitional care excellence at Montefiore Medical Center in the Bronx, New York, referencing the time-to-benefit data in FINEARTS-HF.
So if patients are doing research about transplants, what they read and hear on the internet is that it’s all inpatient. As I said, if you read anywhere—especially, we've been doing this for 10 years now—it’s hard to believe there weren’t a lot of institutions doing outpatient transplants. And so they're like, “What do you mean?”
Related Videos Related Content Advertisement June 11th 2025 Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.
Pharmacists are central to these efforts, ensuring that pharmacogenetic data are interpreted correctly and applied consistently across inpatient and outpatient settings. Their role extends to formulary management, provider education, and protocol development—contributing to greater operational efficiency and higher patient satisfaction.
Materials and Methods The primary objective was to compare the FN rate within 20 days of chemotherapy administration in patients who received a CSF during inpatient admission and had a transportation barrier to health care (group 1) vs patients without a transportation barrier to health care (group 2).
doi:10.1016/S0049-0172(97)80049-2 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. December 21, 2004. Subscribe Now!
Pharmacy Times : How does the team ensure smooth transitions from inpatient to outpatient transplant care, particularly regarding medication management?
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
Patients 18 years or older with inpatient admission to SMV were included in the review. Patients were excluded if they had a primary mental health diagnosis of a substance use disorder or no documented Behavioral Health Initial Assessment Form in the electronic medical record.
Cytokine release syndrome was seen in 78% (all grade 1 or 2), immune effector cell-associated neurotoxicity syndrome occurred in 12% (1% each grade 3 and 4; no grade 5), and neutropenia in 62% of trial participants. At 9 months, duration of response was 75%, progression-free survival was 64%, and overall survival was 80%.
Traditionally administered in inpatient or observation settings due to concerns of cytokine release syndrome (CRS) and other acute toxicities, step-up dosing (SUD) regimens have emerged as a strategy to mitigate these risks.
Author(s): Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief Yes. 5 The Most Significant Driver of Health Care Spend Isn’t Drugs—It Isn’t Even Close Pharmaceutical manufacturers are a frequent punching bag for politicians, mostly because they are easy targets, and they tend to have more visible out-of-pocket exposure.
All children are susceptible to the disease, but those with chronic illnesses or weakened immune systems are at heightened risk. These variations highlight the challenges present in estimating utilities for acute diseases in pediatric patients, according to insights from the trial published in PharmacoEconomics.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content